Soligenix (SNGX) Q3 2025 earnings summary

Executive summary

• Focused on developing and commercializing therapies for rare diseases, with two segments: Specialized BioTherapeutics and Public Health Solutions.

• Key pipeline programs include HyBryte™ for CTCL, SGX302 for psoriasis, SGX942/SGX945 for inflammatory diseases, and multiple vaccine candidates.

• Ongoing clinical trials and regulatory engagement, including a second Phase 3 trial for HyBryte™ and expansion into new indications.

Financial highlights

• Net loss of $2.53 million for Q3 2025, up from $1.72 million in Q3 2024; net loss of $8.18 million for the nine months ended September 30, 2025, compared to $5.28 million in the prior year period.

• Research and development expenses rose to $1.58 million for Q3 2025 (from $0.97 million) and $5.20 million for the nine months (from $2.56 million), mainly due to clinical trial costs.

• General and administrative expenses were $996,604 for Q3 2025 and $3.17 million for the nine months, both slightly higher year-over-year.

• Cash and cash equivalents were $10.53 million as of September 30, 2025, up from $7.82 million at year-end 2024, primarily due to a $7.5 million public offering.

• Working capital increased to $7.46 million from $3.98 million at year-end 2024.

Outlook and guidance

• Sufficient resources to support operations and development activities for at least the next twelve months.

• Plans to submit additional grant applications, pursue partnerships, and explore further equity, royalty, or debt financing.

• Research and development expenditures expected to be approximately $3.8 million over the next 12 months, with no anticipated contract or grant reimbursements.